Logo image of TEM

TEMPUS AI INC (TEM) Stock Fundamental Analysis

NASDAQ:TEM - US88023B1035 - Common Stock

81.3485 USD
+1.73 (+2.17%)
Last: 9/8/2025, 12:21:14 PM
Fundamental Rating

3

TEM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. While TEM seems to be doing ok healthwise, there are quite some concerns on its profitability. TEM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TEM had negative earnings in the past year.
TEM had a negative operating cash flow in the past year.
In the past 5 years TEM always reported negative net income.
TEM had a negative operating cash flow in each of the past 5 years.
TEM Yearly Net Income VS EBIT VS OCF VS FCFTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -12.29%, TEM perfoms like the industry average, outperforming 43.64% of the companies in the same industry.
With a Return On Equity value of -64.52%, TEM is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -12.29%
ROE -64.52%
ROIC N/A
ROA(3y)-60.21%
ROA(5y)-54.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TEM Yearly ROA, ROE, ROICTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

TEM has a Gross Margin of 60.73%. This is in the better half of the industry: TEM outperforms 80.00% of its industry peers.
TEM's Gross Margin has improved in the last couple of years.
TEM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.22%
GM growth 5Y16.28%
TEM Yearly Profit, Operating, Gross MarginsTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TEM has been reduced compared to 1 year ago.
The number of shares outstanding for TEM has been reduced compared to 5 years ago.
The debt/assets ratio for TEM has been reduced compared to a year ago.
TEM Yearly Shares OutstandingTEM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
TEM Yearly Total Debt VS Total AssetsTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 4.64 indicates that TEM is not in any danger for bankruptcy at the moment.
TEM has a better Altman-Z score (4.64) than 81.82% of its industry peers.
TEM has a Debt/Equity ratio of 2.58. This is a high value indicating a heavy dependency on external financing.
TEM has a Debt to Equity ratio of 2.58. This is amonst the worse of the industry: TEM underperforms 87.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Altman-Z 4.64
ROIC/WACCN/A
WACC10.37%
TEM Yearly LT Debt VS Equity VS FCFTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TEM has a Current Ratio of 1.54. This is a normal value and indicates that TEM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.54, TEM is doing worse than 74.55% of the companies in the same industry.
TEM has a Quick Ratio of 1.43. This is a normal value and indicates that TEM is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.43, TEM is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.43
TEM Yearly Current Assets VS Current LiabilitesTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.61% over the past year.
The Revenue has grown by 59.84% in the past year. This is a very strong growth!
The Revenue has been growing by 62.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)85.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.08%
Revenue 1Y (TTM)59.84%
Revenue growth 3Y39.06%
Revenue growth 5Y62.05%
Sales Q2Q%89.57%

3.2 Future

TEM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.58% yearly.
Based on estimates for the next years, TEM will show a very strong growth in Revenue. The Revenue will grow by 38.52% on average per year.
EPS Next Y69.81%
EPS Next 2Y40.77%
EPS Next 3Y29.58%
EPS Next 5YN/A
Revenue Next Year80.87%
Revenue Next 2Y49.6%
Revenue Next 3Y38.52%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TEM Yearly Revenue VS EstimatesTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
TEM Yearly EPS VS EstimatesTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TEM. In the last year negative earnings were reported.
Also next year TEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TEM Price Earnings VS Forward Price EarningsTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TEM Per share dataTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

TEM's earnings are expected to grow with 29.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.77%
EPS Next 3Y29.58%

More info and screens

0

5. Dividend

5.1 Amount

TEM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPUS AI INC

NASDAQ:TEM (9/8/2025, 12:21:14 PM)

81.3485

+1.73 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners37.97%
Inst Owner Change40.65%
Ins Owners4.35%
Ins Owner Change-1.2%
Market Cap14.13B
Analysts77.78
Price Target73.19 (-10.03%)
Short Float %26.53%
Short Ratio2.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.58%
Min EPS beat(2)10.18%
Max EPS beat(2)16.99%
EPS beat(4)4
Avg EPS beat(4)14.69%
Min EPS beat(4)10.18%
Max EPS beat(4)20.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.49%
Min Revenue beat(2)2.05%
Max Revenue beat(2)4.94%
Revenue beat(4)2
Avg Revenue beat(4)1.15%
Min Revenue beat(4)-2.18%
Max Revenue beat(4)4.94%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.59%
PT rev (3m)7.62%
EPS NQ rev (1m)1.31%
EPS NQ rev (3m)-48.66%
EPS NY rev (1m)-3.91%
EPS NY rev (3m)-7.27%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)7.82%
Revenue NY rev (1m)1.03%
Revenue NY rev (3m)1.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.85
P/FCF N/A
P/OCF N/A
P/B 45.65
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS5.48
BVpS1.78
TBVpS-2.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.29%
ROE -64.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.73%
FCFM N/A
ROA(3y)-60.21%
ROA(5y)-54.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.22%
GM growth 5Y16.28%
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.05%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.43
Altman-Z 4.64
F-Score4
WACC10.37%
ROIC/WACCN/A
Cap/Depr(3y)74.55%
Cap/Depr(5y)66.22%
Cap/Sales(3y)5.14%
Cap/Sales(5y)5.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.08%
EPS Next Y69.81%
EPS Next 2Y40.77%
EPS Next 3Y29.58%
EPS Next 5YN/A
Revenue 1Y (TTM)59.84%
Revenue growth 3Y39.06%
Revenue growth 5Y62.05%
Sales Q2Q%89.57%
Revenue Next Year80.87%
Revenue Next 2Y49.6%
Revenue Next 3Y38.52%
Revenue Next 5YN/A
EBIT growth 1Y65.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.23%
EBIT Next 3Y46%
EBIT Next 5YN/A
FCF growth 1Y15.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.8%
OCF growth 3YN/A
OCF growth 5YN/A